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Systematic review 
The use of mobile devices to help patients with cancer to meet 
their illness-related information needs in non-inpatient settings: 
A systematic review 
Introduction 
It is estimated that one in two people in Great Britain will develop some form of cancer 
during their lifetime [1]. In 2017, 359,000 new cases of cancer were diagnosed in the UK 
and the rate of incidence is increasing [2]. However, survival rates have doubled in the UK 
in the last 40 years and so, for many patients, cancer is a chronic condition with which they 
live for many years [2]. Subsequently, there has been a shift from inpatient to outpatient 
and community cancer care, where patients are required to manage their condition at 
home, away from regular supervision by clinicians. This change in care requires patients to 
take a more active role in their treatment and survivorship. Patients are often faced with an 
uncertain future, unfamiliar tests and procedures, complex decisions about treatment 
options, treatment-related side-effects and lifestyle changes. In order to take a more active 
role in their care, and to cope with and manage these changes to daily life, patients require 
relevant information [3]. Research has established that patients with cancer have a wide 
range of information needs throughout their illness. Studies suggest that patients generally 
want information on the extent of the disease, likelihood of cure and prognosis, available 
treatments, side-effects of treatment, self-care and return to normal life [4-6]. Other, less 
urgent, information needs include the impact of cancer and/or treatment on social 
activities, family and friends, mental wellbeing and sexual activity, and the risk of family and 
friends getting cancer [4-6]. A need is described as a desire to receive support with an 
experienced problem [7] and so an information need can be described as the more specific 
desire for informational support. It is important to note that an information need is 
separate from other types of needs, such as emotional or practical needs, however 
information related to other types of illness-related needs can enable patients to meet these 
other needs. For example, access to information on services that provide psychological 
support enables patients to contact those services and meet their emotional needs. For the 
purpose of this paper, the term Ǯillness-related information needsǯ therefore refers to any 
type of illness-related information that is needed by a patient, such as information related to 
the disease itself, treatment, psychological support services, practical support and so on.  
 
While many people with cancer want as much information as possible about their condition 
and related issues [8], studies across the US and Europe have reported very high rates of 
unmet information needs [4, 9]. As well as limiting patientsǯ ability to participate in their 
care, there is evidence to suggest that unmet information needs are associated with a lower 
quality of life, losing a sense of control over oneǯs life, increased anxiety and depression, and 
dissatisfaction with care [10-13]. The introduction of Smart technology has provided a new 
platform for delivering information-based interventions to patients. Smart devices, such as 
Smartphones and tablet computers, are called ǮSmartǯ due to their advanced capabilities in 
comparison to older devices. For example, old generation mobile phones served the sole 
purpose of sending and receiving communications in the form of text messages and voice 
calls, whereas the new generation of devices have dramatically enhanced power and 
capabilities, and an increasing list of software applications ȋ ǮappsǯȌ. As well as customised 
apps, Smartphones and tablet computers are typically equipped with a touchscreen 
interface, Internet access, digital cameras, music players, GPS systems and much more. 
Tablet computers typically offer a larger touchscreen interface compared to Smartphones. 
Most mobile phones that are made and sold today can be described as Smartphones, as even 
the cheapest, less advanced mobile phones available offer the same types of functions as the 
most expensive and advanced Smartphones on the market. The more expensive 
Smartphones and tablet computers are also made affordable by low monthly payment 
plans. 
 
Apps that are built for Smart devices are able to make use of their enhanced capabilities. 
Many companies have created apps so that it is easy for consumers to find and use their 
services and it is now commonplace for people to use apps daily for communication with 
family and friends, banking, shopping, emailing, gaming or consulting the news and weather 
[14]. Due to the many advantages of Smart technology, approximately 93% of adults in the 
UK now personally own or use a mobile phone, of whom 71% specify that they own a 
Smartphone and over two thirds own or have access to a tablet computer [15]. Importantly, 
similar statistics of ownership and use have been reported in cancer patient populations 
[16, 17]. For example, one survey of 210 patients with breast cancer reported that 97% 
(n=204) of patients owned a mobile, of which 69% (n=145) specified a Smartphone, and 
83% (n=174) reported using their mobile phone several times a day, in comparison to a 
computer by 52% (n=109) [17]. Over half of these patients used their mobile phones for ǮSmartǯ activities, such as accessing websites ȋͷ͵%, n=111), emailing (51%, n=107) or 
planning or scheduling (49%, n=103). As studies highlight the increasing use of Smart 
devices surpassing that of conventional computers and laptops, it is important to deliver 
interventions using the platforms that are preferred by patients [17]. Furthermore, 
interventions delivered via Smart devices have the potential to benefit cancer care due to 
the wide reach to patients at the point of need and lower cost compared to traditional 
healthcare interventions, as well as enabling access to tailored healthcare to those in 
resource-poor settings or those facing access barriers to traditional healthcare [18, 19]. 
Subsequently, the UK government has encouraged the integration of interventions 
delivered by mobile technology into traditional healthcare services since the early ʹͲͲͲǯs 
[20]. Furthermore, key reviews over the last few years, such as NHS Five Year Forward [21] 
and the Wachter review [22], have highlighted the importance of, and urgent push for, 
digitisation in the NHS, in order for it to continue to provide a high level of healthcare at an 
affordable cost. 
 
Over the last decade, interventions have been developed and delivered via a range of Smart 
devices, including Smartphones and tablet computers, as well as older mobile devices, such 
as old generation mobile phones, Personal Digital Assistants (PDAs) and other Ǯhandheldǯ 
devices that have enhanced capabilities, such as Internet access and real-time data 
transmission. This range of devices will therefore be referred to as Ǯmobileǯ devices 
throughout this paper, as in the relevant body of literature, as they have been primarily 
designed to be used when on the move and can be stored away easily on your person due to 
their compact size. Due to the many advantages of mobile devices, there has been prolific 
development of Ǯmobileǯ interventions over the last decade in order to facilitate patientsǯ 
self-management of chronic conditions, such as diabetes, heart disease and asthma, where 
patients are at home, without the supervision of a healthcare professional [23]. Studies have 
found that these interventions may improve patientsǯ biological markers of disease, quality 
of life, communication with clinicians and family, and adherence to medication, whilst 
reducing health service costs [23-25]. Following the early indicators of the effectiveness of 
this type of intervention for other chronic conditions, there has been development of mobile 
interventions to support patients with cancer.  
 
Several existing systematic and scoping reviews have explored the general use of mobile 
devices for patients with cancer [26-31]. Findings from these reviews show that 
interventions delivered via mobile devices have been developed for a range of purposes, 
including the prevention, detection, and management of cancer; however, most 
interventions have been designed to support patients during the treatment phase, with 
fewer interventions developed to assist prevention, diagnosis, follow up and survivorship. 
However, there has not yet been a review that identifies how interventions delivered via 
mobile devices have been specifically used to enable patients with cancer to meet their 
illness-related information needs in non-inpatient settings. The current article therefore 
presents a systematic review and critical appraisal of studies describing the use of 
interventions delivered via mobile devices that are designed to enable patients with cancer 
to meet their illness-related information needs in non-inpatient settings. Specifically, the 
effects and feasibility of this type of intervention were assessed. This review focused on 
mobile devices due to the growing number of patients that own this type of technology and 
the advantages of mobile devices in comparison to older types of technology, such as 
accessibility (e.g. cost), portability and enhanced capabilities.  
Methods 
This systematic review followed the PRISMA (preferred reporting items for systematic 
reviews and meta-analysis) guidelines for the conduct of systematic reviews [32]. The 
review was registered on the International Prospective Register of Systematic Reviews 
(PROSPERO) to prevent duplication (registration number: CRD42014010614). At all stages 
of the search, data extraction and quality appraisal, 10% of studies were independently 
double checked for consistency by another researcher. Discrepancies were resolved 
through discussion. 
Identification and screening 
A systematic search of titles and abstracts was conducted in MEDLINE (1946-2017), 
EMBASE (1947-2017) and PsychINFO (1806-2017) databases up to January 2017. Search 
terms focused on three concepts critical to the review question: Ǯmobile devicesǯ, 
Ǯinformation needsǯ and Ǯcancerǯ (Multimedia appendix 1). Terms relating to the same concept were combined using the Boolean operator ǮORǯ, and different concepts were 
combined using the operator ǮANDǯ. Duplicates were electronically removed using the OV)D 
de-duplicate function prior to review of abstracts. Titles and abstracts of citations were 
screened for appropriate studies. References of included articles were searched for further 
studies.  
 
The aim of this review was to assess data on the effects and feasibility of this type of 
intervention, provided by empirical studies. Prior to the search, it was therefore decided 
that grey literature would not be searched as these studies are not peer-reviewed and are 
unlikely to contain empirical data. Identification of studies included a four stage process of 
identification, screening, eligibility assessment and inclusion [32]. In order to be as inclusive 
as possible, there were no restrictions on study methodology or date of publication. 
However, searches were limited to include only human studies and those written in English. 
Included studies were required to meet the following criteria: 1) interventions were 
delivered by a mobile or handheld device (e.g. mobile phone, personal digital assistant), 2) 
interventions attempted to meet patientsǯ illness-related information needs, 3) primary 
participants were patients with cancer who were undergoing treatment, and 4) 
interventions were for use in non-inpatient settings, or non-inpatient and inpatient settings. 
Only those participants who currently had cancer were included in this review as cancer 
survivors may have different information needs to those who are currently undergoing 
treatment for cancer. Additionally, only interventions that were used to support patients in 
non-inpatient settings were included, as this is where patients are now primarily managed 
for the majority of their time during their illness.  
Eligibility and inclusion  
Searches during the identification stage generated 1,020 citations. A total of 54 articles 
were considered appropriate for eligibility screening and an additional 14 articles were 
identified through references. The full-texts of these 68 articles were screened using the 
inclusion criteria, which resulted in the exclusion of a further 45 articles. Reasons for 
exclusion of articles are documented in the PRISMA flowchart (Figure 1). As a result, 23 
articles were included in the review.  
Data extraction and synthesis 
Data were extracted onto a template under the following headings; research identification 
(authors, year of publication, country of study sample, study population), intervention 
(intervention type, mobile device type), research methods (study design, method, data 
analysis), outcome measures, principal findings, and quality appraisal. Due to a lack of 
suitable data, a meta-analysis was not conducted. A narrative synthesis was performed and 
the findings were organised by common themes found across studies [33]. 
Quality appraisal 
Included studies were assessed for methodological quality using the Critical Appraisal Skills 
Programme (CASP) checklists for quantitative and qualitative research [34]. The quality of each 
study was assessed according to each domain included in the checklists, including methodology, 
design, recruitment, data collection, data analysis, ethical issues, reporting of findings and 
contribution to research. The overall quality of the studies was categorised as good, medium or 
poor. The checklists each consisted of ten sections of appraisal questions; one point was assigned 
for satisfying the criteria for each section, however half a point was awarded for a section if 
researchers deemed some of the criteria to be satisfied. A total score of 1-5 was considered Ǯpoorǯ 
quality, 6-7.5 was considered Ǯmediumǯ quality and ͺ-ͳͲ was considered Ǯgoodǯ quality.  
 
 
 
 
 
 
Figure 1. PRISMA flowchart. 
Results 
Description of included studies 
A total of 20 studies were described by the 23 included articles (Table 1). Within these 20 
studies, 14 different interventions were identified. The Advanced Symptom Management System 
(ASyMS) was used in six studies (described by nine of the 23 articles) and the Cancer Care Home 
Telehealth intervention (CCHT) was used in two studies (described by two of the 23 articles). 
The remaining 12 articles described 12 separate intervention studies. Of the 23 articles, there 
were 13 early-phase feasibility studies, one full RCT, three pilot RCTs, three process evaluations, 
one matched-case control study, a secondary qualitative analysis of data generated by an RCT 
included in this review and an analysis of software-logged data from a feasibility study included 
in this review. Sample sizes of patients ranged from n= 4 to n=125, with 13 studies consisting of 
25 participants or less. Of the 23 articles included, twelve were of medium quality, nine were 
were of poor quality and two were of good quality (Table 2, multimedia appendix 22).  
Sample characteristics 
Patients with a wide range of cancer types were included in studies. A total of 17 studies were of 
adult patients and three studies were of children or adolescent patients. Ages of adult patients 
ranged between 24-87 years and ages of child/adolescent participants ranged from 8-18 years. 
Nineteen studies included non-inpatient participants only. Nine studies provided participants 
with a mobile device on entry to the study, a further four studies provided devices for 
participants but participants needed to have a telephone landline in order to participate, two 
studies required participants to own a mobile device and five studies failed to report whether 
participants were required to own a mobile device in order to participate in the study or 
whether a device was provided for the study period. It is also worth noting that one study that provided a mobile device for participants only included those who were Ǯable and willingǯ to use 
a mobile device and another study excluded participants if they had poor proficiency with the 
device.  
Description of the interventions 
Types of mobile devices 
Ten interventions were run on mobile phones; nine of which used Smartphones. One 
intervention that required participants to use their own mobile phone for the study included 
both Smartphones and non-Smartphones. Four interventions were run on tablets and two were 
run on a PDA (a palmtop computer that functions as a personal organiser but also provides access to the )nternetȌ. A further four interventions were run on Ǯhandheld devicesǯ which were 
attached to the participantsǯ telephone line. Studies that used a handheld device did not report 
the functions of this type of mobile device; however, these devices are typically the most limited 
device type in terms of functions. Studies published from 2013 onwards used more advanced 
Smartphones and tablet computers that are commonly used today, such as iPhones and iPads.  
Intervention characteristics 
Two interventions were primarily designed to directly increase patientsǯ knowledge of their 
upcoming surgical operations and coping with cancer-related pain, respectively. One further intervention study primarily aimed to improve patientsǯ communication of symptoms to 
clinicians in consultations, thereby facilitating information exchange. The primary aim of the 
remaining seventeen intervention studies was to improve the monitoring and management of 
treatment-related symptoms. These interventions provided treatment-related self-care information following patientsǯ symptom reports and/or included a system where clinicians 
would be alerted to contact patients and exchange symptom-related information in order to 
manage severe symptoms. One of these seventeen interventions also provided cognitive and 
behavioural skills training in non-pharmacological pain management strategies. Study periods 
ranged from five days to six months, however some study periods may have been longer due to the duration of participantsǯ treatment, which was not reported. 
 
Table 1. Characteristics of included studies.  
Study Study 
population 
Intervention Methods Outcome measures 
 [35] 4 adolescent 
patients. Non-
Hodgkins 
lymphoma and 
osteosarcoma. 
Age range 13-
15 years. UK.  
PDA, symptom-
monitoring for 
one cycle of 
chemotherapy 
(2 weeks). 
Mobile device 
provided.  
Mixed methods, 
pilot RCT. Semi-
structured 
questionnaires, 
interviews. 
Narrative summary 
of findings. 
Patientsǯ perceptions of 
the intervention (effects 
of the intervention, 
acceptability).   
 [36] 9 adult 
patients. GI, 
lung, 
pancreatic, 
urogenital 
cancers, 
osteosarcoma, 
unknown/ 
other cancers. 
Mean age 58 
years. 
Netherlands. 
Mobile phone, 
pain 
monitoring for 
four weeks. 
Access to own 
mobile device 
required.   
Quantitative, 
feasibility study. 
Questionnaires. 
Paired t-tests.  
Pain, quality of life, 
satisfaction with the 
intervention.  
 [37] 125 adult 
patients. Lung, 
head and neck, 
colorectal, 
other cancers. 
Mean age 63 
years. US.  
Handheld 
device, 
symptom-
monitoring for 
six months. 
Access to home 
telephone line 
required.   
Quantitative, 
matched-case 
control study. 
Electronic medical 
records. 
Multivariate 
regression. 
Number of preventable 
service uses (i.e. 
unplanned clinical 
visits), and cancer-
related service uses (i.e. 
expected clinical visits) 
over a six-month period.   
 [38] 48 adult 
patients. Lung, 
head and neck, 
colorectal, 
other cancers. 
Mean age 64 
years. US.  
Handheld 
device, 
symptom-
monitoring for 
six months. 
Access to home 
telephone line 
required.   
Quantitative, 
feasibility study. 
Questionnaires, 
medical records. 
Descriptive 
statistics, linear 
mixed regression. 
Patientsǯ cooperation 
with the intervention 
(adherence) and health-
related quality of life 
during cancer treatment. 
 [39] 20 adult 
patients, 18 of 
which had 
colorectal 
cancers. 
Median age 58 
years. US.  
Tablet 
computer, 
symptom 
monitoring for 
6-24 days, 
depending on 
time between 
operation and 
clinic visit. 
Mobile device 
provided 
(participants 
excluded for 
poor 
proficiency).  
Mixed methods, 
feasibility study. 
Questionnaires. 
Descriptive 
statistics, qualitative 
data was 
summarized 
narratively.  
Adherence, patient 
perceptions of the 
intervention (effects of 
the intervention).  
[40] 39 adult 
patients. Breast 
cancer. Median 
age in 
intervention 
group 54 years. 
Ireland.  
Tablet, 
information 
provision prior 
to surgery. One 
week. Mobile 
device 
provided.  
Quantitative, pilot 
RCT. 
Questionnaires. 
Mann-Whitney tests, Fischerǯs Exact 
tests.  
Anxiety and depression, 
mental adjustment to 
cancer and satisfaction 
with information 
received. 
[41] 12 adult 
patients from 
intervention 
arm of Kearney 
et al. (2009). 
Colorectal and 
breast cancer. 
Mean age 50 
years, age 
range 38-66 
years. UK.  
Mobile phone, 
symptom-
monitoring for 
four weeks of 
chemotherapy 
(12-16 weeks). 
Provision of 
device 
unknown. 
Qualitative, 
secondary analysis. 
Semi-structured 
interviews. 
Foucauldian 
approach with focus 
on surveillance and 
power. 
Patientsǯ perceptions of 
the intervention (effects 
of the intervention).  
[42] 12 adolescent 
patients. 
Leukemia, 
tumours of the 
central nervous 
system.  Mean 
age 12 years.  
US.  
Tablet, pain 
monitoring for 
ten days. 
Mobile device 
provided.  
Quantitative, 
feasibility study. 
Questionnaires. 
Descriptive 
statistics. One-
sample Wilcoxon 
signed rank tests 
were performed to 
determine whether 
the observed 
median was equal to 
the middle value of 
the scale for each 
test.  
Patient perceptions of 
the intervention 
(satisfaction, perceived 
usefulness), symptom 
assessment, pain 
assessment, pain-related 
coping strategies. 
[43] 44 adult 
patients. Head 
and neck 
cancers. Mean 
age 59 years. 
US.  
Handheld 
device, 
symptom-
monitoring for 
the duration of 
treatment, 
average 70 
days (around 
10 weeks). 
Access to home 
telephone line 
required.   
Mixed methods, 
process evaluation 
(from a RCT). 
Interviews, 
telephone 
questionnaires. 
Descriptive 
statistics, 
correlation analysis, 
descriptive 
qualitative analysis. 
Feasibility (median and 
modal use, nurse 
initiated contacts), 
satisfaction with the 
intervention, and long-
term impact of the 
intervention. Narrative 
responses and a post-
study survey provided 
additional data 
examining feasibility and 
satisfaction with the 
intervention. While 
outcomes of the clinical 
trial are not the subject 
of this article, the results 
of quality of life and 
symptom burden 
measures for the 
treatment group were 
reported.  
 
 [44] 15 adult 
patients. Lung 
and colorectal 
cancer. Age 
range 24-77 
years. UK. 
Handheld 
device, 
symptom-
monitoring for 
two cycles of 
chemotherapy 
(approx. 6-8 
weeks). Access 
to home 
telephone line 
required.   
Mixed methods, 
feasibility study. 
Semi-structured 
questionnaires, 
semi-structured 
interviews, software 
log of activity 
(reported in McGee 
and Gray (2005)). 
Descriptive 
statistics, thematic 
content analysis. 
Patientsǯ perceptions of 
the intervention (effects 
of the intervention).  
[45] 112 adult 
patients. 
Breast, lung or 
colorectal 
cancer. Mean 
age 56 years. 
UK.  
Mobile phone, 
symptom-
monitoring for 
four weeks of 
chemotherapy 
(12-16 weeks). 
Provision of 
device 
unknown. 
Quantitative, RCT. 
Logistic regression. 
 
 
 
 
 
Incidence, severity and 
distress of six 
chemotherapy-related 
symptoms (nausea, 
vomiting, fatigue, 
mucositis, hand/foot 
syndrome, diarrhoea). 
[46] 10 adult 
patients. Breast 
and lung 
cancer. Age 
range 44-74 
years. UK.  
Mobile phone, 
symptom-
monitoring for 
two weeks. 
Provision of 
device 
unknown. 
Mixed methods, 
process evaluation 
(from pilot RCT). 
Semi-structured 
questionnaires, 
semi-structured 
interviews. 
Patientsǯ perceptions of 
the intervention (effects 
of intervention, 
acceptability).  
Descriptive 
statistics, thematic 
content analysis. 
[47] 16 adult 
patients. Lung 
cancer. Mean 
age 64 years. 
UK.  
Mobile phone, 
symptom 
monitoring for 
duration of 
radiotherapy 
treatment plus 
one month 
post-treatment. 
Provision of 
device 
unknown. 
Mixed-methods, 
feasibility study. 
Semi-structured 
questionnaires, 
semi-structured 
interviews. 
Descriptive 
statistics, t-tests, 
Mann-Whitney U 
tests, 1-way ANOVA 
tests, Kruskal-Wallis 
tests, Fisher Exact 
tests, Wilcoxon 
signed ranks tests, 
McNemar tests, 
thematic analysis.  
Patientsǯ perceptions of 
the intervention 
(feasibility, acceptability) 
anxiety levels, self-care 
self-efficacy, well-being, 
quality of life, physical 
symptom distress.    
[48] 21 adult 
patients 
receiving 
palliative care. 
Breast, 
prostate, oral, 
respiratory, 
GI/colorectal, 
gynaecology, 
myeloma, 
unknown 
primary 
cancers. Mean 
age 64 years, 
age range 40-
87 years. UK.  
Mobile phone, 
symptom-
monitoring for 
30 days. 
Provision of 
device 
unknown.  
Mixed methods, 
feasibility study. 
Questionnaires, 
semi-structured 
interviews. 
Descriptive 
statistics, thematic 
analysis. 
Patientsǯ perceptions of 
the intervention (effects 
of intervention, 
acceptability).  
[49] 53 adult 
patients from 
the 
intervention 
arm of Kearney 
et al. (2009). 
Breast, lung or 
colorectal 
cancer. Mean 
age approx. 55 
years. UK.  
Mobile phone, 
symptom-
monitoring for 
four weeks of 
chemotherapy 
(12-16 weeks). 
Provision of 
device 
unknown. 
Mixed methods, 
process evaluation.  
Semi-structured 
questionnaires, 
semi-structured 
interviews. 
Descriptive 
statistics, thematic 
content analysis. 
Patientsǯ perceptions of 
the intervention (effects 
of intervention, 
acceptability).  
[50] 15 adult 
patients. Lung 
and colorectal 
cancer. Age 
range 24-77 
years. UK. 
Handheld 
device, 
symptom-
monitoring for 
two cycles of 
chemotherapy 
(approx. 6-8 
weeks). Access 
to home 
telephone line 
required.   
Software log of 
activity, descriptive 
statistics.  
Software-logged activity; 
modem events, 
questionnaire events, 
and information access 
events. 
[51] 60 adult 
patients. Breast 
cancer. Mean 
age 51 years. 
US.  
PDA, symptom 
communication 
with clinicians, 
for 160 days 
(around 5 
months). 
Provision of 
device 
unknown.  
Mixed methods, 
pilot RCT. 
Questionnaires,  
interviews. 
Descriptive 
statistics, random-
effects linear 
regression, 
qualitative analysis. 
 
Pain, fatigue and 
depression symptoms, patientsǯ (RQOL and 
communication self-
efficacy. Patientsǯ 
perceptions of the 
intervention (effects of 
the intervention).  
[52] 25 adult 
patients. 
Breast, lung, 
colorectal, 
prostate 
cancers. Mean 
age 53 years. 
US.  
Tablet, pain 
coping skills. 
Four sessions 
(30-45 
minutes). 
Mobile device 
provided.   
Mixed methods, 
feasibility study. 
Questionnaires, 
qualitative data 
collection method 
not specified.  
Descriptive 
statistics, paired 
sample t-tests. 
Patientsǯ perceptions 
(effects of the 
interventions , 
acceptability). 
Pain severity, physical 
functioning, physical 
symptoms, psychological 
distress, self-efficacy for 
pain management, pain 
catastrophizing.   
 [53] 14 adolescent 
patients. ALL, 
AML, Ewing's 
sarcoma, non-
Hodgkin's 
lymphoma, 
osteosarcoma, 
rhabdomyo-
sarcoma, other. 
Mean age 13 
years. Canada.  
Mobile phone, 
pain-related 
symptom-
monitoring for 
two weeks. 
Mobile device 
provided.   
Mixed methods, 
feasibility study. 
Semi-structured 
questionnaires. 
Descriptive 
statistics, t tests. 
 
 
Patientsǯ perceptions of 
the intervention 
(acceptability) and 
feasibility (adherence).  
[54] 9 adult 
patients. 
Prostate 
cancer. Mean 
age 69 years. 
Sweden. 
Mobile phone, 
symptom 
monitoring for 
two weeks. 
Mobile device 
provided.  
Mixed methods, 
feasibility study. 
Focus group, 
interviews. 
Descriptive 
statistics, content 
analysis.  
Software logged data 
(symptom alerts) patient 
perceptions of the 
intervention 
(acceptability).  
[55] 6 adult 
patients. Colon 
cancer. Age 
range 54-76 
years, median 
age 64 years. 
UK.  
Mobile phone, 
symptom-
monitoring for 
two cycles of 
chemotherapy 
(approx. 6-8 
weeks). Mobile 
device 
provided.  
Mixed methods, 
feasibility study. 
Informal interviews. 
Descriptive 
statistics, narrative 
summary of results 
due to informal 
nature of 
interviews. 
Feasibility (symptom 
alerts, reasons for alerts, 
adherence). Patientsǯ 
perceptions of the 
intervention (effects of 
intervention, 
acceptability).   
[56] 26 adult 
patients. 
Breast, 
colorectal 
cancers. Mean 
age 57 years. 
UK.  
Mobile phone, 
symptom 
monitoring for 
approx. five 
cycles of 
chemotherapy. 
Mobile device 
provided 
(participants 
required to be 
able to use 
device). 
Mixed methods, 
feasibility study. 
Questionnaires, 
interviews. 
Descriptive 
statistics, thematic 
analysis.  
Feasibility (symptom 
alerts generated, reasons 
for alerts, advice given). 
Patientsǯ perceptions of 
the intervention (effects 
of the intervention).  
[57] 68 adult 
patients. 
Breast, GI, head 
& neck, lung, 
lymphoma, 
ovarian, 
cervical, 
bladder 
cancers. 
Median age 50 
years. 
Singapore. 
Mobile phone, 
symptom-
monitoring for 
five days. 
Access to own 
mobile device 
required.   
Mixed methods, 
feasibility study. 
Semi-structured 
telephone 
questionnaires. 
Descriptive 
statistics, Pearson's 
chi-squared and 
Fisher's exact tests, 
qualitative analysis. 
Feasibility (adherence), number of pharmacistsǯ 
interventions, patientsǯ 
perceptions of the 
intervention (usefulness, 
acceptability).  
 
 
Themes 
Findings from the narrative synthesis were organised into two main themes: (1) acceptability of 
the interventions, which included the subthemes of perceived usefulness, perceived ease of use, 
and adherence to interventions, and (2) benefits of the interventions, which included the 
subthemes of symptom management, patient empowerment, reassurance and reduced anxiety, 
patient-clinician communication and health-related quality of life (Table 2, multimedia appendix 
2).   
Acceptability   
Perceived usefulness 
The mobile interventions were perceived as useful by the majority of patients, particularly 
the self-care advice provided in response to symptom reports [36, 41-44, 46, 49, 54, 56, 57]. 
Qualitative interviews with patients who took part in an RCT reported that the information 
provided them with expectations for their treatment, reminded them to watch for 
symptoms and suggested helpful home remedies [43]. Qualitative interviews from another 
RCT showed that patients were positive about the real-time, fast response of the clinician-
alerting facility [49]. However, interviews from a feasibility study found that some patients 
felt that the depth of the self-care information was insufficient and repetitive [44] and two 
further feasibility studies revealed variation in use of the self-care advice/information 
pages [47, 50, 54]. One study reported that whilst over half of patients (62%, n=37 of 60 
patients) found a mobile phone, symptom-monitoring intervention useful, patients with 
lower education and chemotherapy-naïve patients rated the intervention significantly more 
useful than those with higher education (75%, n= 45, vs 35%, n=21) or those who had 
received chemotherapy before (82%, n=49, vs 53%, n=32) [57].  
 
Perceived ease of use  
Almost all patients reported that they found the mobile interventions easy to use, 
regardless of age, cancer type and experience with technology [36, 43, 44, 46, 47, 48, 53-55]. 
For example, one study reported that all 44 patients from the intervention arm of an RCT 
reported a handheld device to be very easy (n=37, 85%) or easy (n=7, 15%) to use [43]. 
Similarly, a feasibility study reported that although 66% (n=12) of 18 patients had little 
prior computer experience, at post-study all 11 patients who had received the intervention 
reported that they felt comfortable using the handheld device [44]. A similar study 
including a sample of 13 patients receiving palliative care reported that patients lacked 
confidence and experience in using technology, particularly the Internet and PDAs [48]. 
Post-study, all patients reported that they felt very comfortable (n=6) or comfortable (n=7) 
using the mobile phone intervention, however five patients required help from family to 
complete the electronic questionnaire due to poor physical health. Interviews and 
questionnaire findings from an RCT and feasibility study suggested that daily use of a mobile phone intervention did not impact on patientsǯ daily routines or privacy and was not 
perceived as burdensome or too time-consuming [36, 49]. The majority of patients 
experienced no or very few technical problems with their mobile devices, however those 
who did tended to encounter problems with Internet connection or practical problems with 
the device itself [46, 48-51, 55, 56]. 
 
Adherence to mobile interventions 
Studies generally reported high adherence rates to the mobile interventions, regardless of  
the length of the study [36, 38, 39, 43, 51-53, 55-57]. A pilot RCT of 44 patients reported 
that patients used a handheld device consistently for an average of 10 weeks [51]. Similar 
results were reported in another pilot RCT of 60 patients that used a PDA for approximately 
22 weeks, where 83% (n=49) of patients completed symptom inventories and 90% (n=54) 
watched communication videos when instructed [51]. A feasibility study with longest study 
period included in this review (up to six months) reported that the mean adherence of 48 
patients to daily dialogues with a care coordinator using a handheld device was 84%, with a 
decrease in adherence as treatment progressed [38]. One study suggested that adherence 
might be affected by the type of device used or experience with this type of technology, as 
adherence was significantly higher among Smartphone users compared to basic mobile 
phones users (87%, n=52, vs 47%, n=28) [57]. The most common reasons reported for non 
adherence to interventions were hospitalisation, forgetfulness and technical problems [43, 
51].  
 
Benefits of the interventions 
Symptom management 
The majority of patients perceived the mobile interventions to be helpful in monitoring 
their treatment-related symptoms. Additionally, studies highlighted that mobile 
interventions are able to capture patient information and outcomes that are not captured 
via conventional reporting, such as questionnaires [39, 42, 44, 46, 48, 52, 54, 56]. However, 
an RCT of 112 breast, lung and colorectal cancer patients showed mixed results [45]. 
Authors hypothesised that a real-time, symptom monitoring intervention would facilitate 
better measurement of six chemotherapy-related symptoms, resulting in more timely 
interventions. Although two out of six monitored symptoms were significantly different 
between groups, there were conflicting findings of significantly lower reports of fatigue and 
significantly higher reports of hand/foot syndrome in the intervention vs. control group. 
There was some evidence to suggest that symptom-monitoring interventions have the 
potential to reduce the unnecessary use of healthcare services by improving symptom 
management [36, 37, 56]. For example, a matched case-control study of 125 patients investigated the effects of a handheld device intervention by measuring patientsǯ 
unexpected and expected use of cancer-related services over six months [37]. Findings 
showed that the intervention group had significantly lower use of unexpected care services 
and significantly higher use of most expected care services, however contrastingly, patients 
in the intervention group had significantly fewer expected clinic visits compared to controls. 
Authors suggested this contrasting result was possibly due to patients resolving issues with 
the care coordinator prior to an expected clinic visit thereby reducing the need for the visit.  
 
The majority of symptom-monitoring intervention studies further reported that patients 
perceived that the interventions had led to improved symptom management [39, 43, 46, 47, 
49, 52, 56]. A process evaluation from an RCT of 44 patients found that 52% (n=23) 
reported that they were much better, and 44% (n=19) somewhat better, at managing their 
condition as a result of a handheld, symptom-monitoring intervention [43]. A more recent 
feasibility study reported that participants showed significantly decreased pain severity, 
physical symptoms, psychological distress, and pain catastrophizing following a tablet-run 
pain-coping skills intervention [52]. Similarly, a feasibility study of a mobile phone 
intervention [36] reported that the mean pain score of participants from the start to end of 
a feasibility study decreased non-significantly, but when measured using the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30), the mean pain score decreased significantly from 56 to 35. Furthermore, two 
studies reported that patients were admitted to hospital as a result of a real-time symptom 
monitoring intervention, which resulted in proactive management of those patientsǯ 
symptoms [36, 56].  
 
Patient empowerment 
Some studies suggested that remote monitoring of symptoms empowered patients to 
participate in their care and better manage their condition due to increased knowledge of 
their condition and symptom management strategies provided by the mobile interventions 
[39, 42-44, 56]. In qualitative interviews with 11 lung and colorectal cancer patients, 
patients explained that this type of intervention had increased their understanding of their 
symptom-related problems and consequently, their confidence in their abilities to manage 
symptoms [44]. Furthermore, six patients that used a mobile phone, symptom-monitoring 
intervention reported that they felt more involved and responsible for their care [55]. More 
recent studies supported these results [52, 56]. A feasibility study of a mobile phone 
intervention reported that patients felt more in control of their care and had increased 
confidence to self-manage their condition at home as a result of the intervention [56]. 
Similarly, a feasibility study of a tablet device intervention showed that out of 25 patients, 
95% (n=20) reported that the intervention helped them to understand the experience of 
pain and 90% (n=19) of participants felt the intervention had taught them skills that 
improved their pain coping; however, an observed increase in pain self-efficacy following 
the pain-related coping skills intervention was not significant [52]. Finally, a similar 
feasibility study of a tablet device intervention [42] reported on the perceived usefulness of 
pain management strategies used by children, including self-talk, heat application and social 
support and suggested that this type of intervention provided patients with the opportunity 
to increase their self-efficacy in coping with pain during treatment.  
 
Reassurance and reduced anxiety 
The majority of studies reported that patients perceived cliniciansǯ surveillance of, and 
response to, their symptoms as reassuring, however there were some mixed findings for the 
effects of information on levels of anxiety [40, 41, 44, 46-49, 54-56]. Qualitative interviews 
with 12 patients from a process evaluation of an RCT of a mobile phone, symptom-
monitoring intervention reported that patients felt secure in the knowledge that clinicians 
were being alerted about their symptoms [49]. Results from a secondary analysis of these 
interviews suggested that patients viewed their surveillance as liberating, freeing them of 
the worry of making a decision to contact clinicians themselves [41]. Similar perceptions 
were reported by patients in a smaller pilot RCT, where patients felt the mobile phone 
intervention allowed them to relax [46]. In contrast, a feasibility study of a mobile symptom 
monitoring intervention reported no change in anxiety levels [47] and one study suggested 
that information interventions may increase patientsǯ anxiety [ͶͲ]. A pilot RCT study of a 
tablet-based information provision intervention found that there was a significant increase 
in pre-operative fatalism in the intervention group and anxiety was significantly lower in 
the control group at seven days post operation [40]. This study suggests that increasing patientsǯ knowledge of treatment could potentially increase rather than reduce their 
anxiety. However, authors reported that some women were anxious about using a tablet 
computer with which they were unfamiliar and this may have increased their anxiety [40]. 
Additionally, the follow up period was short at seven days post-surgery.  
 
Patient-clinician communication  
Many patients perceived that communication with clinicians had improved or that their 
relationship with clinicians had strengthened as a result of the interventions [35, 39, 41, 43, 
46, 47, 55]. A post-study questionnaire of 44 patients from an RCT of a handheld, symptom-
monitoring intervention found that 65% (n=29) of patients were more satisfied with the 
communication with their clinicians [43]. A secondary qualitative analysis of patient 
interviews from an RCT of a mobile phone, symptom-monitoring intervention reported that 
patients felt the intervention gave them easier access to cancer specialists, as well as 
increasing the amount of communication with clinicians [41]. Authors suggested that easier 
access to clinicians may change the dynamic of the traditional hierarchical models of 
healthcare to a more patient-centred model, as clinicians are more responsive to the patientsǯ reports and needs. Furthermore, two feasibility studies found that as the intervention prompted clinicians to contact the patients, patientsǯ uncertainty about 
whether to contact their clinicians when needed was reduced and they felt less Ǯbothersomeǯ to their clinicians [Ͷ͹, 55].  
 
Heath-related quality of life (HRQOL)  
Studies reported mixed findings of the interventions on patientsǯ (RQOL [36, 38, 43, 47, 51]. 
An RCT of 44 patients using a handheld device during treatment periods, which required 
patients to report symptoms three to five times daily, reported significant positive 
correlations between usage of the intervention and physical well-being and emotional well-
being scores during treatment [43]. A feasibility study of 48 patients using a handheld 
device to answer daily symptom questions from a care coordinator found a clinically significant improvement of ͸.͵ points in patientsǯ (RQOL between baseline and six months 
[38]. This study suggested that a symptom-monitoring intervention could reassure patients 
who are anxious during treatment, thereby maintaining their HRQOL. In contrast, although 
one feasibility study reported a non-significant increase in quality of life following a pain-
monitoring intervention [36], one feasibility study reported no change in wellbeing [47], 
however both studies had small sample sizes. Negative findings were also reported in a 
pilot RCT study of 60 patients using a PDA device, where patients reported symptoms 
weekly during treatment periods and viewed videos on how to communicate their 
symptoms to their clinicians prior to their consultations [51]. This study found that patientsǯ (RQOL were not significantly different between groups. Furthermore, the pre-post 
treatment decrease in HRQOL was generally greater among the intervention group. Authors 
suggested that this result might be due to the intervention drawing attention to the 
symptoms experienced by patients in the intervention group [51]. However, due to the 
methodological differences between studies, such as study design, measurement of HRQOL 
and intervention intensity (e.g. intervention functions, interaction with patient and duration 
of intervention), meaningful comparison of these studies is not possible, though it is 
possible that intervention intensity is partly responsible for these mixed findings.  
 
Discussion 
Principal Results 
To our knowledge, this is the first systematic review to identify and critically appraise 
studies that describe the use of mobile interventions designed to enable patients with 
cancer to meet their illness-related information needs in non-inpatient settings. The 
primary aim of the majority of intervention studies included in this review was to improve the monitoring and management of patientsǯ treatment-related symptoms, which included 
the provision of self-care information and interactive information exchange with clinicians. 
Although these interventions attempted to educate patients in some way, the information 
and skills provided were solely related to their treatment. There were no interventions that 
primarily aimed to meet patientsǯ full range of illness-related information needs by 
increasing their understanding of their condition and other important, related issues. 
Overall, findings from this review indicated that patients reported this type of technology 
and intervention to be acceptable, regardless of age, experience with technology, cancer 
type or stage of cancer. Patients perceived the mobile interventions to be useful, 
particularly the self-care advice and the fast response from clinicians. Additionally, there 
was evidence to suggest that patients with lower education or chemotherapy-naïve patients 
could benefit most. Patients also reported that they found the mobile interventions easy to 
use and non-intrusive on their daily routine, with few technical problems encountered. 
Adherence to interventions was generally high, however there was considerable variation 
in usage of the different intervention components within and between studies. Reported 
benefits of the interventions included improved symptom management, patient 
empowerment and improved clinician-patient communication, however mixed findings were reported for patientsǯ anxiety and HRQOL.  
Findings in the context of other literature  
A plethora of mobile interventions have been developed to support patients remotely with a 
range of chronic conditions, such as diabetes and heart disease, and findings of the present 
review mirror this previous literature which has found mobile technology to be an 
acceptable platform to deliver interventions to patients with chronic conditions, regardless of the patientsǯ type of disease, age, gender and experience with technology [23-25]. The 
finding that few technical problems were experienced in the present review is in contrast to 
previous literature, where many patients have cited technical difficulties as a barrier to use 
and satisfaction with the intervention [58-60]. This contrast finding may be due to the fact 
that many interventions for other conditions, such as diabetes and heart disease, require 
additional technological devices to monitor symptoms (e.g. glucose monitor, blood pressure 
monitor), which would increase the likelihood of technical errors.  
 
Adherence rates to mobile interventions included in this review were generally high 
throughout the study periods, which were up to six months, however engagement appeared 
to decrease over the course of the intervention. These patterns mirror those of studies of 
mobile interventions for other chronic conditions, which included study periods of 12 
months [60]. Despite generally high rates of adherence for this type of intervention, there 
appears to be considerable variation in usage of the different intervention components 
within and between studies, such as the self-care advice pages. It is important that future 
studies better describe interventions by coding intervention functions in order to 
determine the components that are responsible for positive outcomes and enable more 
systematic evaluations [61].    
 
Patients recognised the benefits of real-time symptom monitoring interventions, such as 
increased knowledge and confidence to participate in self-care, which appeared to result in 
improved management of symptoms. Additionally, the capability of this technology to 
capture patient-reported outcomes in real-time may be of clinical importance as it 
promotes timely intervention [60, 61]. This could reduce the amount of preventable 
hospitalisations, as suggested by some studies included in this review. Previous studies of 
mobile symptom-monitoring or adherence interventions have shown similar findings, 
including improvements to symptoms, such as an increased blood glucose control, 
increased self-management behaviours, such as increased adherence to treatment, and 
fewer hospital admissions [23-25, 60].  
 
In the present review, patients reported that communication with their clinician had 
improved as a result of the interventions and that found cliniciansǯ monitoring of their 
symptoms to be reassuring. Similar findings have been reported in studies of symptom-
monitoring interventions for other chronic conditions, where patients described feelings of 
security, felt that they had not been forgotten and were receiving good care outside of 
hospital and clinics [62, 63]. Mobile interventions offer an inexpensive way to bridge the 
gap between patients and clinicians and increase their contact at a time when patients 
require more support following a shift from inpatient to outpatient cancer care.  
 
Findings of the present review reported mixed findings on the impact of mobile interventions on patientsǯ anxiety and HRQOL, however few studies included in this review 
measured these outcomes. For some patients, having more knowledge on their condition 
might reduce their anxiety due to the development of realistic expectations of the future 
and preparedness for treatment-related side effects, resulting in a better experience. Conversely, information might also increase patientsǯ anxiety by drawing attention to their 
condition, unknown symptoms or the risks of treatment. The few studies that have measured the impact of mobile devices on patientsǯ quality of life or emotional distress for 
other chronic conditions have also reported mixed findings [64, 65]. However, some studies have highlighted the potential of Smartphones to specifically increase patientsǯ awareness 
of stress and emotional well-being, by recording moods during both health and illness, and 
deliver therapeutic interventions accordingly, which has led to reduced anxiety [65, 66]. 
Mobile interventions can provide an opportunity to increase patientsǯ access to 
psychological support and deliver psychological interventions remotely at a time when 
patients are vulnerable.  
Quality of studies 
The large number of early-phase studies in this field means that many studies included in 
the present review used an uncontrolled design. The current evidence for the effectiveness 
and feasibility of mobile interventions to support patients with cancer is therefore limited. 
Although these studies highlighted the potential benefits of such interventions, RCTs are 
needed to support the findings of this review. Additionally, most studies included in this 
review were critically appraised as poor or medium quality, which further limits the 
conclusions that can be drawn from these studies. Limitations of some studies included 
small sample sizes, samples limited to single cancer types, under-reporting of response 
rates and details of participants who were lost to follow up, and short study periods. Other 
limitations included the failure of studies to explore the opinions of patients with negative 
views and the economic costs of these types of intervention. Additionally, some studies only 
included participants who had access to their own device or were already able to 
competently use a mobile device. This inclusion criterion may have biased findings, as those 
who participated in these studies may have had more favourable perceptions of mobile 
interventions than those who were unable to participate. Finally, many studies relied on 
self-reported data which may have been affected by recall or the Hawthorne effect [67], 
where participants may have changed their behaviour due to knowingly being observed.  
Strengths and limitations of this review 
The AMSTAR checklist (A Measurement Tool to Assess Systematic Reviews) was used to assess the quality of this systematic review. Strengths of this review include an Ǯa prioriǯ 
design, ten percent of studies at each stage of the search, data extraction and quality 
appraisal was checked for consistency by another researcher, multiple databases and 
references of included studies were searched, study characteristics were reported, and the 
studies were critically appraised on their quality, which was taken into account when 
drawing conclusions. However, the present review has several limitations. A meta-analysis 
was not conducted as included studies did not have suitable data to aggregate, however a 
narrative synthesis was considered to be a suitable alternative method to explore the 
findings of these studies. Other limitations include poor indexing of studies, which may have 
limited the number of studies included in this review, and a number of potential studies 
were found through searching references of included studies. Finally, this review did not 
report on the perceptions and experiences of healthcare professionals that participated in 
some studies as this was beyond the scope of the review.  
Implications for policy and practice 
This review has several implications. Firstly, it established that a wide range of patients 
with cancer perceived mobile devices to be an acceptable medium to receive interventions 
remotely. Secondly, this type of intervention appears to have the potential to provide a 
range of benefits for patients, clinicians and the healthcare service. Specifically, findings of 
this review suggest that symptom-monitoring interventions that provide treatment-related 
information to patients have the potential to improve patientsǯ self-management of their condition and provide clinicians with a better understanding of patientsǯ symptom 
experiences, whilst improving the patient-clinician relationship. This may lead to earlier 
detection of treatment-related side-effects and timely intervention, which could reduce 
costs for the healthcare system. This type of intervention also has the potential to sustain or improve patientsǯ well-being during a time where they typically experience a decrease in 
well-being. Importantly, this review established that, to date, mobile interventions for 
patients with cancer have only attempted to meet a single type of information need (e.g. 
treatment-related symptom information, coping skills), which has typically been achieved 
indirectly.  
 
This review has also identified that more comprehensive interventions are required for 
patients currently receiving treatment in order for them to meet their full range of illness-
related information needs in non-inpatient settings, where they are now spending the 
majority of their time away from the direct supervision of their clinicians. The literature has 
established that the type of illness-related information required by patients with cancer 
varies within and between patients with cancer and any unmet information needs will likely 
depend on the information provided by their healthcare team. It is therefore unlikely that a 
single intervention can include this large amount of information in a single intervention and tailor it to an individualsǯ condition and location for related services. (owever, there 
already exists a huge number of useful and reputable cancer-related information resources 
and services throughout the UK, such as information websites, telephone helplines, support 
groups, and financial services, which are developed and run by reputable cancer charities 
and health organisations. Intervention developers could incorporate and organise existing 
services within interventions in order to arm patients with the tools that they need to be 
able to obtain relevant information.  
 
The majority of interventions identified in this review required continued monitoring and 
interaction from clinicians, however involving clinicians places unrealistic demands on an 
already stretched healthcare service. Few mobile interventions have been developed to be 
used independently by patients. Development of such an intervention would support the 
initiatives of UK governments and health organisations to empower patients to take a more 
active role in their care by increasing support for patients in non-inpatient settings and 
harnessing the power of technology in order to do so [21, 22].  
Conclusions 
This is the first systematic review to identify how mobile devices have previously been used 
to help patients with cancer to meet their illness-related information needs in non-inpatient 
settings. So far, the majority of mobile interventions have been designed to enable cliniciansǯ surveillance of patients remotely in the form of symptom-monitoring 
interventions. Despite promising findings, these interventions have sought only to increase patientsǯ knowledge of their treatment-related side-effects and coping strategies. More 
comprehensive interventions are required for patients who are currently receiving 
treatment in order to meet their full range of illness-related information needs when 
managing their condition in non-inpatient settings. Given the variation of information needs 
within and between patients, it may be useful for intervention developers to incorporate 
existing cancer-related information resources and services into interventions in order to 
enable patients to obtain their desired information. Nevertheless, mobile devices appear to 
be an acceptable platform to deliver interventions remotely to patients with cancer. This 
review also highlights the early stage of the research that is being conducted in this area, 
which limits the conclusions that can be drawn. Following on from early-phase feasibility 
studies, RCTs are needed to support the findings of this review, further determine the 
effectiveness of this type of intervention to improve patient outcomes and to support the 
transfer of interventions into standard practice.  
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